Hiva Mohammadizad1, Mehdi Shahbazi1, Mohammad Reza Hasanjani Roushan2, Mehdi Soltanzadeh-Yamchi1, Mousa Mohammadnia-Afrouzi3. 1. Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran; Immunoregulation Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran; Department of Immunology, School of Medicine, Babol University of Medical Sciences, Babol, Iran. 2. Infectious Diseases and Tropical Medicine Research Center, Babol University of Medical Sciences, Babol, Iran. 3. Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran; Immunoregulation Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran; Department of Immunology, School of Medicine, Babol University of Medical Sciences, Babol, Iran. Electronic address: m.mohammadnia@mubabol.ac.ir.
Abstract
BACKGROUND: Chronic HBV infection presents weak or no virus-specific T-cell responses, implying to an exhausted phenotype, characterized by overexpression of several inhibitory receptors. In the present study, it was aimed to characterize the panel of inhibitory molecules on the CD8+ T cells in patients with active chronic HBV infection. METHODS: In this study, 31 active and 32 inactive individuals with chronic HBV infection were recruited. Peripheral blood mononuclear cells were isolated and a multicolor flow cytometry was applied to evaluate the surface inhibitory molecules of TIM3, PD-1, and CD39. RESULTS: CD8+ T cells expressing TIM3 were significantly higher in cases with active chronic HBV infection compared to inactive chronic HBV group (8.43 ± 1.4 vs. 5.15 ± 1.43; P < 0.0001). CD8+TIM3+PD-1+ T cells were significantly higher in active chronic HBV cases in comparison to the inactive chronic HBV subjects (4.26 ± 1.04 vs. 3.41 ± 0.74; P < 0.001). Different subpopulations of the CD8+ T cells were correlated with the duration of infection and HBV DNA load in the cases with active chronic HBV infection. CONCLUSION: It appears that CD8+ TIM3+ T cells are the major exhausted phenotype of T cells during the active state of HBV infection.
BACKGROUND:Chronic HBV infection presents weak or no virus-specific T-cell responses, implying to an exhausted phenotype, characterized by overexpression of several inhibitory receptors. In the present study, it was aimed to characterize the panel of inhibitory molecules on the CD8+ T cells in patients with active chronic HBV infection. METHODS: In this study, 31 active and 32 inactive individuals with chronic HBV infection were recruited. Peripheral blood mononuclear cells were isolated and a multicolor flow cytometry was applied to evaluate the surface inhibitory molecules of TIM3, PD-1, and CD39. RESULTS:CD8+ T cells expressing TIM3 were significantly higher in cases with active chronic HBV infection compared to inactive chronic HBV group (8.43 ± 1.4 vs. 5.15 ± 1.43; P < 0.0001). CD8+TIM3+PD-1+ T cells were significantly higher in active chronic HBV cases in comparison to the inactive chronic HBV subjects (4.26 ± 1.04 vs. 3.41 ± 0.74; P < 0.001). Different subpopulations of the CD8+ T cells were correlated with the duration of infection and HBV DNA load in the cases with active chronic HBV infection. CONCLUSION: It appears that CD8+ TIM3+ T cells are the major exhausted phenotype of T cells during the active state of HBV infection.
Authors: Marissa Herrmann; Sophia Schulte; Nils H Wildner; Melanie Wittner; Thomas Theo Brehm; Michael Ramharter; Robin Woost; Ansgar W Lohse; Thomas Jacobs; Julian Schulze Zur Wiesch Journal: Front Immunol Date: 2020-08-26 Impact factor: 7.561
Authors: Thor Ueland; Lars Heggelund; Andreas Lind; Aleksander R Holten; Kristian Tonby; Annika E Michelsen; Synne Jenum; Marthe J Jørgensen; Andreas Barratt-Due; Linda G Skeie; Ingvild Nordøy; Mai Sasaki Aanensen Fraz; Else Quist-Paulsen E; Søren E Pischke; Simreen K Johal; Liv Hesstvedt; Mette Bogen; Børre Fevang; Bente Halvorsen; Fredrik Müller; Gry Kloumann Bekken; Tom E Mollnes; Susanne Dudman; Pål Aukrust; Anne M Dyrhol-Riise; Jan C Holter Journal: J Allergy Clin Immunol Date: 2020-09-21 Impact factor: 10.793